Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | CPA1 | P15085 | 3/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260496 | 0.91 | MME (0.35) | MMEACECPA1ACE2PIP4K2A | |
| SCHEMBL5259088 | 0.86 | ITGB1 (0.41) | ITGB1ITGA4DRD1PPARGFFAR1 | |
| SCHEMBL5262062 | 0.81 | MME (0.33) | MMEACECPA1ACE2DGAT2 | |
| SCHEMBL5333186 | 0.81 | PIM1 (0.34) | ITGB1ITGA4PPARG | |
| SCHEMBL5261691 | 0.78 | DRD1 (0.36) | ITGB1ITGA4KDM4CDRD1PPARG | |
| SCHEMBL5260488 | 0.77 | ITGB1 (0.38) | ITGB1ITGA4KDM4CDRD1PPARG | |
| SCHEMBL5261695 | 0.77 | FFAR1 (0.36) | DRD1FFAR1 | |
| SCHEMBL5262264 | 0.76 | ITGB1 (0.38) | ITGB1ITGA4PPARG | |
| SCHEMBL5260326 | 0.76 | ITGB1 (0.38) | ITGB1ITGA4PPARG | |
| SCHEMBL5263308 | 0.76 | PPARG (0.33) | ITGB1ITGA4DRD1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | MME 588/4885ACE 1634/4885CPA1 1749/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | MME 734/4885ACE 1894/4885CPA1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.